New Clinical Trial with CBD (cannabidiol) for patients with Tuberous Sclerosis and Pharmacoresistant Epilepsy:

 February 2017

The Epilepsy Unit of the Centro Médico Teknon starts the inclusion of patients in a new clinical trial with CBD (cannabidiol) for patients with Pharmacoresistant Epilepsy and Tuberous Sclerosis since one year of age (pediatrics and adult).

This clinical trial is being supervised by the competent health authority and the Ethics Commitee. Trial in all the country.

To be a candidate for the trial, these are the main criteria you must meet:

• Age is between 1 and 65.
• Diagnosed with tuberous sclerosis
• Diagnosed with epilepsy and a minimum of 8 convulsive seizures a month.

For further information, contact with Dr. Hari Bhathal, Principal Investigator and Coordinator in national territory (Spain) of this trial: telf: 933 933 197 mail: tsc.teknon@gmail.com.